Clinical Trial Search

Primary: Number of Participants With Need for Additional Uterotonics (Methylergonovine, Carboprost, Misoprostol) — 80; 80 Participants

Primary: Intracranial Pressure — -0.3; -4.3 cmCSF

Primary: Number of Participants With Intracranial Bleeding and/or Recurrent Ischemic Lesion as Confirmed by MRI Imaging — 47; 48 Participants

Primary: Stroke or Death in the Territory of Qualifying Artery — 5 Participants — p=0.08

Primary: Number of Participants With the Clinically Important Intracranial Bleeding — 48; 1 Participants

Primary: Participants With Modified Rankin Scale (mRS) <=3 - Dichotomized Analysis — 47.6; 44.9 percentage of participants — p=0.554

Primary: Any Stroke or Death Within 30 Days of Enrollment or Any Revascularization Procedure OR an Ischemic Stroke in the Territory of the Symptomatic Intracranial Artery Beyond…

Primary: Number of Participants With Raymond Class I Complete Obliteration at 12 Months — 98 Participants

Primary: Mean Change in Perimetric Mean Deviation — 1.43; 0.71 dB — p=0.05

Primary: Change in Interleukin-1beta Level in Blood (Picogram/Milliliter)

Primary: Number of Study Subjects With Life-threatening Thromboembolic Complications — 1; 0; 0 Participants — p=1.00

Primary: Best Corrected Visual Acuity — 1.1; 1.4 LogMar

Primary: Packing Density With the Number of Coils Implanted — 37.9 percentage of aneurysm volume

Primary: Number of Participants With Progression of Symptomatic Intracranial Stenosis — 20; 32 participants

Primary: mITT Primary Effectiveness Endpoint. Based on Subjects With 100% Occlusion of the Aneurysm Without Clinically Significant Stenosis of the Parent Artery, and Without Any…